We expect consolidation to further strengthen this position, leveraging brand and knowledge across various testing and inspection markets. However capital outlays in establishing a global network of operations and laboratories during the resources boom mean ALS is barely earning its cost of capital on an adjusted basis, and if goodwill is included, returns do not currently meet the cost of capital. This precludes the company from having a moat. Historically, about 60% of earnings were tied to volatile commodity markets, but the end of the resources booms and expansion into segments including environmental, pharmaceutical and food testing reduces this to less than 50%.
Key Investment Factors
Investors should be aware of the inherent volatility around commodity-tied earnings. The mining and energy downturn has demonstrated the vulnerability of businesses tied to resource activity. Although ALS previously benefited from exposure to a robust mining sector, management has astutely grown other parts of the business that are less cyclical. Environmental, pharmaceutical, and asset-care services should remain relatively more resilient. A growing global network reduces region reliance and gives ALS the capability to leverage experience across borders and serve an international client base.
No-Moat ALS’ Coronavirus-Resistant Fiscal 2021 Earnings as Expected; No Change to AUD 5.50 FVE
Our AUD 5.50 fair value estimate for no-moat ALS Limited is unchanged. The materials testing specialist reported a 1.5% decline in underlying fiscal 2021 net profit after tax to AUD 186 million, marginally ahead of our AUD 178 million expectations. We make no material changes to our outlook, including for a 12% increase in underlying fiscal 2022 NPAT to AUD 209 million. ALS paid a higher-than-anticipated fiscal second-half dividend of AUD 14.6 cents against our AUD 12.5 cents target. It brings the full fiscal year to AUD 23.1 cents for a modest 1.9% yield at the current AUD 12.30 share price, franked to 81%. Our fiscal 2022 DPS forecast is little changed at AUD 26 cents, a prospective partially franked yield of 2.1%, again modest.
That said, ALS remains a prospective growth story, not a yield one. Although in this light we remain perplexed by the level of market excitement, the shares are trading at more than double our assessed fair value, at a fiscal 2021 P/E of 32. We determine the current share price implies a whopping five-year EBITDA CAGR of 16.5% to AUD 817 million by fiscal 2026. Underlying fiscal 2021 EBITDA actually fell 1.6% to AUD 373 million. This wasn’t a bad result in lieu of the coronavirus pandemic, but ALS’ business model was always expected to be resilient given its essential service status.
We think we’re being generous enough forecasting five-year EBITDA CAGR of 5.0% to AUD 487 million by fiscal 2026, including a midcycle EBITDA margin of 21.3%, in line with fiscal 2021’s 21.2% actual. This includes strong 8% growth for life sciences, but essentially flat earnings for commodities and industrial including tribology. Our fair value equates to a fiscal 2026 EV/EBITDA of 8.1, P/E of 14.3 and dividend yield of 4.2%, assuming a 60% payout ratio. Life sciences generated just under half of fiscal 2021 EBITDA and comprises approximately 55% of our fair value estimate, followed by minerals at 40%. Industrial comprises the modest 5% balance of fair value.
With respect to fiscal 2021, life sciences and industrial EBITDAs somewhat undershot our forecast, the former steady at AUD 222 million and the latter falling 13% to AUD 33 million. However, the minerals segment shone, EBITDA up 4.5% to AUD 210 million, considerably ahead of our expectations. This speaks to the quality of fiscal 2021 earnings outperformance given innate volatility in minerals’ earnings in contrast to the comparative stability from life sciences. Fiscal 2021 net operating cash flow increased 4% to AUD 270 million as expected. Free cash flow grew 57% but to a lower-than-expected AUD 145 million, due to higher-than anticipated capital expenditure. This leaves net debt at AUD 614 million, higher than expected but creditably down on the previous corresponding period’s AUD 803 million and September 2020’s AUD 675 million print.
ALS Ltd Company Profile
Founded in the 1880s and listing on the ASX in 1952, ALS operates three divisions: commodities, life sciences, and industrial. ALS commodities traditionally generated the majority of underlying earnings, providing geochemistry, metallurgy, inspection and mine site services for the global mining industry. Expansion into environmental, pharmaceutical and food testing areas and commodity price weakness have lessened earnings exposure to commodities.
Source: Morningstar
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.